Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P M Hoff

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Oncology (Williston Park, N.Y.)|February 24, 2001
Novel therapeutic approaches for metastatic colorectal cancerP M Hoff
Investigational New Drugs|November 18, 2000
The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potentialP M Hoff
Oncology (Williston Park, N.Y.)|August 12, 1999
Oxaliplatin and UFT/oral calcium folinate for advanced colorectal carcinomaP M Hoff, R Pazdur
Seminars in Oncology|July 13, 2000
Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agentsP M Hoff, R Pazdur
Oncology (Williston Park, N.Y.)|February 28, 2001
Other fluorinated pyrimidines in the treatment of solid tumorsE D Saad, P M Hoff
Leukemia|February 3, 1998
Comparison of acute myeloid leukemia patients at MD Anderson: 1982-1986 vs 1992-1996P M Hoff, S Pierce, E Estey
Drugs|March 11, 2000
Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracilP M Hoff, Y Lassere, R Pazdur
Drugs & Aging|October 24, 2000
Progress in colorectal cancer chemotherapy: how far have we come, how far to go?M E Royce, P M Hoff, R Pazdur
The Oncologist|October 5, 2001
The evolution of fluoropyrimidine therapy: from intravenous to oralP M Hoff, J Cassidy, H J Schmoll
Current Oncology Reports|December 21, 2000
Novel chemotherapy agents for colorectal cancer: oral fluoropyrimidines, oxaliplatin, and raltitrexedM E Royce, P M Hoff, R Padzur
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Oncology (Williston Park, N.Y.)|February 24, 2001
Novel therapeutic approaches for metastatic colorectal cancerP M Hoff
Investigational New Drugs|November 18, 2000
The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potentialP M Hoff
Oncology (Williston Park, N.Y.)|August 12, 1999
Oxaliplatin and UFT/oral calcium folinate for advanced colorectal carcinomaP M Hoff, R Pazdur
Seminars in Oncology|July 13, 2000
Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agentsP M Hoff, R Pazdur
Oncology (Williston Park, N.Y.)|February 28, 2001
Other fluorinated pyrimidines in the treatment of solid tumorsE D Saad, P M Hoff
Leukemia|February 3, 1998
Comparison of acute myeloid leukemia patients at MD Anderson: 1982-1986 vs 1992-1996P M Hoff, S Pierce, E Estey
Drugs|March 11, 2000
Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracilP M Hoff, Y Lassere, R Pazdur
Drugs & Aging|October 24, 2000
Progress in colorectal cancer chemotherapy: how far have we come, how far to go?M E Royce, P M Hoff, R Pazdur
The Oncologist|October 5, 2001
The evolution of fluoropyrimidine therapy: from intravenous to oralP M Hoff, J Cassidy, H J Schmoll
Current Oncology Reports|December 21, 2000
Novel chemotherapy agents for colorectal cancer: oral fluoropyrimidines, oxaliplatin, and raltitrexedM E Royce, P M Hoff, R Padzur
Pageof 5